Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How Drug Promotion Might Change Under Trump's Rx Pricing Plan

Executive Summary

DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.

You may also be interested in...



Industry Makes A Drug Price Transparency Push In DTC Ads, But Is It Too Little Too Late?

PhRMA unveiled a voluntary policy under which drug makers will provide information in DTC ads about how to access drug prices and cost information. But hours later HHS issued a proposed rule on the same topic, only requiring drug makers to include WAC prices in TV ads. .

Trump's Drug Pricing Blueprint: An Administrative Vs. Legislative Breakdown

Where can HHS go it alone, and where does it need Congress?

'Immediate' Steps To Lower Drug Prices: The HHS Action Plan

Many of blueprint's proposals could be accomplished administratively, but will still be shaped by stakeholder feedback.

Topics

UsernamePublicRestriction

Register

SC141576

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel